Mark is a Lecturer in Cell and Molecular Biology at Glasgow Caledonian University. He has over 12 years of expertise in researching haematological malignancies (blood cancers), including Acute Myeloid Leukaemia (AML) and Multiple Myeloma (MM), and has identified new therapeutically targetable disease mechanisms. His research group is focusing on utilising unique in vitro 3D co-culture systems to more accurately model and target bone marrow microenvironment (BMME) mediated therapy resistance mechanisms in AML and MM. On-going studies are focussing on the contribution of fibroblasts and macrophages towards BMME driven therapy resistance, as well as developing a novel multi-targeting therapeutic antibody for MM patients.
Mark’s lab is collaborating with key academic/clinical researchers: Dr Monica L Guzman (Weill Cornell Medicine, Cornell University, USA), Dr Valerie Ferro and Dr Paul Mulheran (University of Strathclyde) and Prof Helen Wheadon (Paul O’Gorman Leukaemia Research Centre, University of Glasgow UK), as well as biopharmaceutical researchers Dr Simon T Barry (AstraZeneca, UK) and Dr Daniella Zheleva (Cyclacel, UK). Mark currently holds affiliate status at the Institute of the Institute of Infection Immunity & Inflammation, University of Glasgow, and he is a visiting researcher at the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde.
Mark Williams
